(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2007 (18.05.2007)

PCT

(10) International Publication Number
WO 2007/056061 A2

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2006/042812

(22) International Filing Date:
2 November 2006 (02.11.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/732,741 2 November 2005 (02.11.2005) US

(71) Applicants *(for all designated States except US)*: **DUKE UNIVERSITY** [US/US]; M454 Davison Building, Duke University Medical Center, Durham, NC 27710 (US). **UNIVERSITY OF TEXAS M.D.ANDERSON CANCER CENTER** [US/US]; 1515 Holcombe Blvd., Houston, Texas 77030 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SAMPSON, John, H.** [US/US]; C/o Duke University, M454 University Medical Center, Durham, NC 27710 (US). **BIGNER, Darell, D.** [US/US]; C/o Duke University, M454 University Medical Center, Durham, NC 27710 (US). **HEIMBERGER, Amy** [US/US]; C/o University of Texas M.D., Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **MITCHELL, Duane** [US/US]; C/o Duke University, M454 University Medical Center, Durham, NC 27710 (US).

(74) Agent: **KAGAN, Sarah, A.**; Banner & Witcoff, LTD., 11th Floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2007/056061 A2

(54) Title: CONCURRENT CHEMOTHERAPY AND IMMUNOTHERAPY

(57) Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, hi fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.